Aim: The aim of this study is to compare the therapeutic yield of medical thoracoscopy and intrapleural fibrinolysis by streptokinase in complicated parapneumonic effusion and empyema regarding both efficacy and safety.
Introduction
Parapneumonic effusion is a pleural effusion associated with bacterial pneumonia, lung abscess or bronchiectasis. An effusion is called empyema when the concentration of leukocytes becomes macroscopically evident as a thick, highly viscous, whitish-yellow, opaque, and turbid fluid (pus) [1] .
Parapneumonic effusion can be divided into three stages: the exudative phase in which, fluid moves into the pleural space due to locally increased capillary vascular permeability and the activation of immune processes such as neutrophil migration. Pro-inflammatory cytokines including interleukin (IL)-6, IL-8 and tumor necrosis factor alpha (TNF-a) produce changes in the anatomical shape of pleural mesothelial cells creating intercellular 'gaps' which further enhance permeability and additional fluid accumulates. The accumulating pleural fluid has a normal glucose level (>40 mg/dL) and pH (>7. 20) , with no detectable bacteria, and hence no microbiological or biochemical evidence of bacterial invasion. The effusion will usually resolve spontaneously with antibiotic therapy for the underlying pneumonia [2] .
In the fibropurulent phase, the high levels of fibrinolytic activity which characterize the normal pleural space are rapidly depressed and titers of specific inhibitors of fibrinolytic activity such as tissue plasminogen activator inhibitors (PAI) 1 and 2 rise. PAI 1 and 2 and mediators such as TNF-a are directly released from mesothelial cells and are increased in infected pleural fluid compared with fluid from malignancy and other causes. This leads to fibrin deposition over the visceral and parietal pleura, with the division of the pleural space by fibrinous septae, producing fluid loculation and pleural adhesions [3] .
In the organizing stage there is proliferation of fibroblasts and evolution of pleural scarring which forms an inelastic peel on both pleural surfaces with dense fibrous septations across the pleural cavity. As this solid fibrous peel replaces the soft fibrin, lung re-expansion is prevented, impairing lung function [4] .
PPE is categorized to 4 categories for evaluating the risk of poor outcome in patients with PPE based on three variables, pleural space anatomy, pleural fluid bacteriology, and pleural fluid chemistry. Pleural effusion drainage for patients with moderate (category 3) or high (category 4) risk for a poor outcome, but not for patients with very low (category 1) or low (category 2) risk for a poor outcome. infection indicates a need for chest tube drainage. 4-Parapneumonic effusions that do not fulfill any of these criteria for chest tube drainage could be treated with antibiotics alone provided clinical progress is good.
5-Poor clinical progress during treatment with antibiotics
alone should lead to prompt patient review, repeat pleural fluid sampling and probably chest tube drainage [6] .
Patients and methods
This study included 40 patients with complicated parapneumonic effusion and empyema were admitted to chest department Mansoura university hospital from January 2012 to July 2013, informed consent was obtained from all patients. Patients had both symptoms and signs of a bacterial pneumonia and a pleural effusion; fever, productive cough, chest pain and dyspnea. Full laboratory work up was done, plain chest X-ray, trans-thoracic ultrasound chest to detect loculations and CT chest were done before and after intervention. Pleural fluid aspiration was done and sent for biochemical analysis including, pH, LDH, protein content and cellular pattern also Gram stain and culture were done for aerobic and anaerobic organisms prior to initiation of antibiotic therapy. Included patients had frank pus, pH < 7.20, positive Gram stain or culture. Patients were randomly divided into two groups; first group was managed by medical thoracoscopy (MT) and the second group was managed by intercostal tube drainage (ICT) plus intrapleural instillation of streptokinase as fibrinolytic agent. Patients who were diagnosed with tuberculosis, bronchial carcinoma, chronic obstructive airway diseases and diabetic patients were excluded from the study.
Medical thoracoscopy was performed in the first group under local anesthesia and conscious sedation (midazolam 5 mg) in an endoscopy room. Patients were placed in lateral decubitus with the affected side up. The trocar point of entry was chosen by ultrasonography to identify the point where the pus collection is largest and the position of the diaphragm, which is often elevated. 11-mm rigid rod lens telescope (STORZ) was introduced in the pleural cavity, suction of all fluids was done, cutting and removal of adhesions and thickened pleura and opening of multiple loculations were done by using forceps through forceps channel, lastly the pleural cavity was irrigated by normal saline and intercostal tube (30 F) was inserted in the pleural cavity.
To patients undergoing intercostal tube drainage (30 F) insertion in the pleural cavity, after 2 h of drainage, streptokinase 250,000 U in 100 ml of normal saline solution was instillated through intercostal tube to the pleural cavity, tube was clamped for 4 h then unclamped to continue drainage, this procedure was repeated daily for maximum of 5 days. Intercostal tube in both groups was left until fluid drainage becomes less than 100 ml/day. Clinical, laboratory, radiological and hospital stay duration end points were adopted for comparing the two interventions as absence of frank pus in the drainage, fever, leukocytic count, and chest X-ray and CT opacity. Inadequate drainage, was defined on radiological basis as the presence of >50% of the original amount of pleural fluid on a chest X-ray [7] . Patients of both groups received antibiotic therapy covering most likely possible organisms; third generation cephalosporins, respiratory quinolone and metronidazole, later readjusted according to the results of bacterial culture.
Statistical methods
Data were analyzed using SPSS (Statistical Package for Social Sciences) version 15. Qualitative data were presented as number and percent. Comparison between groups was done by Chi-Square test. Quantitative data were presented as mean ± SD. Student's t-test was used to compare between two groups. P < 0.05 was considered to be statistically significant.
Results
This study included 40 patients (24 males and 16 females) with complicated parapneumonic effusion (23 patients) and empyema (17 patients). The patients were randomly divided into two groups, medical thoracoscopy (MT) group and group 2 intercostal tube with streptokinase group and both groups were compared with regard to clinical, laboratory, radiological and hospital stay duration endpoints.
The mean age for group 1 was 45.6 ± 8.9 and the mean age for group 2 was 48.6 ± 12.4. Group 1 included 11 males (55%) and 9 females (45%) while group 2 included 13 males (65%) and 7 females (35%). In group 1, 13 patients (65%) were smokers, 4 patients (20%) were non-smokers and 3 patients (15%) were ex-smokers. In group 2, 9 patients (45%) were smokers, 6 patients (30%) were non-smokers and 5 patients (25%) were ex-smokers (see Table 1 ).
Dyspnea and fever were present in all patients of both groups, chest pain was present in 17 patients (85%) in group 1 and in 18 patients (90%) of group 2, productive cough was present in 15 patients (75%) of group 1 and in 18 patients (90%) of group 2 and hemoptysis was present in only one patient (5%) in each group (see Table 2 ).
Leukocytic count was more in group 1 (14,370 ± 2830) than group 2 (13,550 ± 2780) and ESR was also higher in group 1 (60 ± 34) than group 2 (51 ± 29). The diameter of induration was less than 5 mm in both groups (see Table 3 ).
In group one 2 patients (10%) had yellowish fluid, 10 patients (50%) had turbid fluid and 8 patients (40%) had frank pus, in group two 2 patients (10%) had yellowish fluid, 9 patients (45%) had turbid fluid and 9 patients (45%) had frank pus.
Direct Gram's staining of group 1 patient samples showed no organisms and three of group 2 patient samples (15%)showed Streptococcus pneumoniae. Culture of the pleural The mean value for pleural fluid pH was 6.88 ± 0.25 in group 1 and 6.97 ± 0.17 in group 2. The mean value for pleural fluid protein was 4.14 ± 1.11 in group 1 and 4.05 ± 1.06 in group 2. The mean value for pleural fluid LDH was 491.60 ± 166.11 in group 1 and 457.85 ± 162.30 in group 2 and the mean value for pleural fluid glucose was 42.25 ± 19.01 in group 1 and 37.00 ± 18.58 in group 2 (see Table 4 ).
In group 1, 11 patients (55%) had right sided pleural effusion while 9 patients (45%) had left sided pleural effusion. In group 2, 8 patients (40%) had right sided pleural effusion while 12 patients (60%) had left sided pleural effusion.
In group 1, 7 patients (35%) had total improvement and 13 patients (65%) had partial improvement, in group 2, 2 patients (10%) had no improvement, 1 patient (5%) had total improvement and 17 patients (85%) had partial improvement.
In group 1, 19 patients (95%) had total improvement and 1 patient (5%) had partial improvement, in group 2, 7 patients (35%) had total improvement and 13 patients (65%) had partial improvement.
In group 1, 19 patients (95%) had total improvement and 1 patient (5%) had partial improvement, in group 2, 14 patients (70%) had total improvement and 6 patients (30%) had partial improvement but in CT chest confirmed group 1 but in group 2, 12 patients (60%) had total improvement and 6 patients (40%) had partial improvement (see Table 5 ).
There was a significant difference between both groups. In group 1 only 1 patient persist to drain about 100 ml and was referred to cardiothoracic surgery (see Table 6 ).
In group 1 after the MT no patients were diagnosed with dyspnea, hemoptysis or fever, 1 patient with persistent cough, 2 patients with persistent chest pain and no patients with frank pus with a decrease in WBC count to 9.51 ± 1.28. In group 2 after ICT-SK no patients were diagnosed hemoptysis, 3 patient with persistent cough, 3 patients with persistent chest pain, 1 patient with dyspnea, 1 patient with fever and 1 patient with frank pus with a decrease in WBC count to 9.15 ± 1.34. There was a significant difference in each group but there was no difference in significance between both groups (see Table 7 ).
In group 1, 19 patients (95%) had total improvement and 1 patient (5%) had partial improvement, in group 2, 12 patients (60%) had total improvement and 6 patients (40%) had partial improvement with a significant difference (see Table 8 ).
The duration of hospital stay was 4.70 ± 1.45 days in group 1 and 6.95 ± 2.04 days in group 2 (see Table 9 ).
In group 1 only 3 patients had complications following medical thoracoscopy, one patient had SC emphysema and two patients had mild controlled bleeding and no mortality. In group 2 only 5 patients had complications, one patient had persistent empyema, one patient had mild bleeding, one patient had SC emphysema and two patients had developed mild allergic reaction injections and with no mortality (see Table 10 ).
Image 1 shows multiple loculi Image 2 shows multiple adhesions

Image 3 shows cutting of adhesions by forceps
Image 4 shows pleural space become one pouch at the end of the procedure
Discussion
Parapneumonic effusions and empyemas present difficult diagnostic and therapeutic challenges because of their highly variable clinical presentation and response to therapy. It is estimated that at least 40% of hospitalized patients with pneumonia develop a parapneumonic effusion, which is associated with an increased morbidity and a mortality of 15%. There is a considerable variation in the clinical course of patients with parapneumonic effusions [8] .
The formation of a mature PE can be divided into three stages: (i) the exudative stage, (ii) the fibropurulent stage and (iii) the organization stage. The exudative phase is characterized by a sterile exudate secondary to increased permeability of the visceral pleura. The fibropurulent phase represents pleural infection with the deposition of fibrin on visceral and parietal pleural membranes and the formation of loculations. Pleural fluid glucose and pH decrease and LDH increases in pleural fluid. The organization stage occurs with the influx of fibroblasts into the pleural space and formation of inelastic pleural peels and dense fibrous septations. The rapidity and extent of progression to a mature PE depend on the type and virulence of the pathogen, the patient's host defenses, and the timing and effectiveness of antibiotic therapy. Various classifications have been proposed to clinically stage the extent of pleural inflammation and PPE formation [9] .
The increased viscosity of pleural pus in patients with PE is attributable to high concentrations of DNA resulting from the breakdown of phagocytes, bacteria, and other intrapleural cells. Streptodornase is a mixture of four DNAase enzymes released by streptococci that reduces the viscosity of pus through the digestion of DNA. In combination with fibrinolytic drugs or used as a single agent, streptodornase liquefies pleural pus in vitro from patients and animal models with PE more effectively than urokinase or streptokinase alone. Clinical trials are needed to evaluate the efficacy of streptodornase in combination with fibrinolytic drugs for patients with highly viscous, multiloculated PE that fail chest tube drainage [10] .
Generally accepted indications for the use of thoracoscopy in infected pleural space have yet to be agreed [11, 12] . Some authors maintain that it should be used before positioning a chest tube, when chest tube insertion is indicated [13] . Others consider that it should be used only when a large-caliber chest drain does not bring about reduction of fever and complete radiological resolution of the effusion after 2-3 days [14, 15] .
Medical thoracoscopy, as a drainage procedure intermediate between tube thoracostomy and VATS, is significantly lower in cost and can avoid surgical thoracoscopy under general anesthesia. It is essential that it is performed early in the course of empyema and it is particularly advisable for frail patients at high surgical risk [13] .
Cases on the use of thoracoscopy in pleural space infections are mainly related to empyema and are principally surgical. They generally describe favorable results, with primary success rates (complete recovery without the need for subsequent thoracotomy or conversion of VATS to thoracotomy) of 60-100%. In the present authors' experience of medical thoracoscopy, in 69 cases, the primary success rate was 93% and only five patients needed a surgical intervention by VATS or thoracotomy (unpublished data). The best results were obtained when the method was applied early in the course of the disease [16] . Medical thoracoscopy has played a marginal role in the treatment of empyema for a long time, but has become more and more established in recent years. It can be performed in analgo-sedation in a bronchoscopy suite. It is minimally invasive and costs are much lower compared to surgical VATS. The diagnostic and therapeutic power seems to be comparable to VATS, since several studies show success rates with medical thoracoscopy between 73% and 100% [17] .
Intrapleural fibrinolytic therapy agents offer a promising alternative and have been reported as an effective adjunct to accelerate drainage of loculated effusions in complicated empyema [18] Fibrinolytic agents are believed to work through decreasing fibrinous strands and reopening pleural pores blocked by fibrinous material, permitting pleural resorption. Streptokinase was first used by Tillett in 1949 to lyse fibrinous pleural material and break down loculi. [19] .
Intrapleural fibrinolytic therapy was first used in 1949 by Tillet and Sherry, who used partially purified streptococcal fibrinolysin that contained both streptokinase and streptodornase (a DNAse) to drain infected postoperative hemothoraces [20] .
More recently, observational series and small randomized trials showed that these agents improved pleural fluid drainage, and it was therefore widely assumed they would improve long-term patient outcome. However, a recent large randomized trial showed that these short-term drainage benefits are not associated with reduced mortality, the frequency of surgery, the length of hospital stay or long-term radiological and lung function outcome [6] .
Intrapleural fibrinolytic therapy remains an option for poor surgical candidates who fail chest tube drainage or who require a period of medical stabilization before surgery is performed. Fibrinolytic drugs are most likely to be successful in patients with early PPE. Additional investigations are needed to confirm these recommendations and to evaluate the role of antifibrotic, DNAase, and other fibrinolytic drugs both as primary and adjunctive therapy [21] .
Against this background, the MIST1 trial reported its findings in 2005. The study recruited 454 patients across 52 UK hospitals, and was powered to address whether streptokinase altered combined death and surgical rate. There was no difference between SK and placebo groups in death or surgery analyzed separately, length of hospital stay, radiographic change or lung function at 3 months. Subgroup analyses demonstrated no difference between streptokinase and placebo regardless of characteristic studied (pleural fluid purulence, complicated parapneumonic effusion, short clinical history, initial amount of radiographic effusion) [22] .
Thus, current evidence does not support the routine use of intrapleural fibrinolytic agents. On occasions, such treatment may be indicated for the physical decompression of multiloculated (and so tube drainage resistant) pleural fluid collections that are responsible for dyspnea or respiratory failure if discussion with a thoracic surgeon identifies that either surgery is not immediately possible due to additional patient co-morbidity, the feasibility of transfer to a surgical unit or other clinical or logistical reasons [6] . As we do not have VATS in our hospital we tried to show the efficacy of MT in the management of complicated parapneumonic effusion and empyema comparing it to commonly used therapies tube thoracostomy with streptokinase as initial treatments. We found that MT is uniformly successful, well tolerated, and associated with better outcome.
In our study success rate of intrapleural streptokinase was 60% in group 2 less than Bergh [25] as they studied less number of patients (12, 15 and 16, respectively) and compared it to placebo injection in the intercostal tube, our success rate was more than Fraedrich et al. (44%) [26] as they studied larger number of patients (27 patients) with more patient needed decortication (15 patients) and our success rate was near to Laisaar et al. (68%) [27] and Temes et al. (69%) [28] as they studied similar number of patients (21 and 19 patients respectively).
In some series SK treatment is reported to have no beneficial effect on hospital stay, given a mean of 3 weeks [29] . In our study, however, mean hospital stay was significantly shorter for Group 2 patients about 1 week as we started injection earlier.
Our results in group 1 were comparable to Wait et al. [7] study who compared streptokinase injection to VATS their success rate in VATS (91%) was similar to ours (95%) and they studied less number of patients (11 patients).
We have no any serious complications where in group 1 only 3 patients had complications following medical thoracoscopy, one patient had SC emphysema and two patients had mild controlled bleeding and no mortality. In group 2 only 5 patients had complications, one patient had persistent empyema, one patient had mild bleeding, one patient had SC emphysema and two patients had developed mild allergic reaction and with no mortality. These results are comparable to Wait et al. [7] study in which only two patients developed mild allergic reaction at the 4 th and 5th injection and two patients complained of back pain.
Conclusion
Medical thoracoscopy is superior to streptokinase fibrinolysis in complicated parapneumonic effusions and empyema in terms of safety and efficacy.
